Unveiling the contributions of immunization for progressing towards Universal Health Coverage.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
31 12 2022
Historique:
pubmed: 4 3 2022
medline: 15 4 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

The aim of the United Nations' Sustainable Development Goal (SDG)3 is to ensure healthy lives and promote well-being for all, at all ages; including reducing maternal and child mortality, combating communicable and non-communicable diseases, and achieving Universal Health Coverage (UHC). UHC aims to provide everyone with equal access to quality essential and comprehensive healthcare services including preventions, interventions, and treatments, without exposing them to financial hardship. Making progress toward UHC requires significant investment in technical and financial resources and countries are pursuing the implementation of cost-saving measures within health systems to help them achieve UHC. Whilst many countries are far from attaining UHC, all countries, particularly low- and middle-income countries, can take steps toward achieving UHC. This paper discusses key data showing how immunization is a fundamental, cost-effective tool for reducing morbidity and mortality associated with infectious disease in all populations, creating more productive communities, reducing treatment costs, and consequently, facilitating social and economic advancement. Immunization is key to advancing toward UHC by relieving the burden that diseases place on the healthcare services, freeing essential resources to use elsewhere within the healthcare system. Immunization is an essential, readily available strategy that countries can deploy to achieve UHC and the SDG3 agenda.

Identifiants

pubmed: 35239460
doi: 10.1080/21645515.2022.2036048
pmc: PMC9009948
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2036048

Références

Nature. 2019 Nov;575(7784):S48-S50
pubmed: 31776498
Bull World Health Organ. 2014 May 1;92(5):314-5
pubmed: 24839319
J Perinatol. 2020 Jun;40(6):844-857
pubmed: 32341454
Emerg Infect Dis. 2016 Jun;22(6):1106-8
pubmed: 27191621
Vaccine. 2011 Aug 11;29(35):5846-9
pubmed: 21722688
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):25-31
pubmed: 31802153
Lancet. 2021 Aug 7;398(10299):522-534
pubmed: 34273292
JAMA. 2020 Oct 20;324(15):1495-1496
pubmed: 33044484
BMC Public Health. 2019 Sep 3;19(1):1218
pubmed: 31481050
J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1231-1238
pubmed: 29955836
Scand J Infect Dis. 2011 Sep;43(9):683-9
pubmed: 21604922
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130433
pubmed: 24821919
Econ Disaster Clim Chang. 2020;4(3):431-451
pubmed: 32838118
Immunity. 2017 Mar 21;46(3):350-363
pubmed: 28329702
Biomed Res Int. 2014;2014:707691
pubmed: 24868544
Biologicals. 2021 Jun;71:55-60
pubmed: 33966960
Health Aff (Millwood). 2011 Jun;30(6):1021-8
pubmed: 21653952
MMWR Recomm Rep. 2011 Jan 28;60(2):1-64
pubmed: 21293327
Physiol Rev. 2018 Jul 1;98(3):1417-1464
pubmed: 29767563
N Engl J Med. 2013 Feb 7;368(6):551-60
pubmed: 23388006
Ann Med. 2018 May;50(3):193-208
pubmed: 29308916
Vaccine. 2017 Jul 24;35(33):4064-4071
pubmed: 28647170
N Engl J Med. 2014 Jun 5;370(23):2211-8
pubmed: 24897084
Euro Surveill. 2014 Oct 09;19(40):20921
pubmed: 25323077
Bull World Health Organ. 2010 Jun;88(6):402
pubmed: 20539847
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Vaccine. 2016 Dec 20;34(52):6707-6714
pubmed: 27773475
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
Ann Med. 2021 Dec;53(1):2286-2297
pubmed: 34854789
Clin Infect Dis. 2010 Nov 1;51(9):1007-16
pubmed: 20887208
Clin Microbiol Infect. 2012 Oct;18 Suppl 5:100-8
pubmed: 22862783
Vaccine. 2016 Nov 21;34(48):5827-5832
pubmed: 27342915
Health Aff (Millwood). 2020 Aug;39(8):1343-1353
pubmed: 32744930

Auteurs

Martin O C Ota (MOC)

Medical Affairs, GSK, Medical Affairs, Wavre, Belgium.

Jose C de Moraes (JC)

Department of Collective Health, Faculty of Medical Sciences of Santa Casa de Sao Paulo, Sao Paulo, Brazil.

Ivo Vojtek (I)

Medical Affairs, GSK, Medical Affairs, Wavre, Belgium.

Dagna Constenla (D)

Medical Affairs, GSK, US Research & Development, Saloui Center, Rockville, MD,USA.

T Mark Doherty (TM)

Medical Affairs, GSK, Medical Affairs, Brondfby, Denmark.

Otavio Cintra (O)

Medical Affairs, GSK, Medical Affairs, Rio de Janeiro, Brazil.

Joses M Kirigia (JM)

African Sustainable Development Research Consortium (ASDRC), Nairobi, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH